Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Pliant Therapeutics, a US-based fibrosis therapy developer based on research at University of California (UC), San Francisco, yesterday raised $100m in a series C round led by pharmaceutical firm Novartis. Redmile, Farallon Capital Management, Cormorant Asset Management, Surveyor Capital, Logos Capital, Eventide Asset Management, Cowen Healthcare Investments, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.